Monopar Therapeutics Secures License for Wilson Disease Treatment

Monopar Therapeutics Inc ( (MNPR) ) just unveiled an update.

Monopar Therapeutics has secured an exclusive global license from Alexion Pharmaceuticals to develop and commercialize ALXN-1840, a promising treatment for Wilson disease, following a successful Phase 3 trial. The agreement entails an upfront payment of $4 million, equity in Monopar, and milestone payments up to $94 million, plus royalties. Despite regulatory challenges and the need for further funding, Monopar is focused on advancing ALXN-1840, targeting severe Wilson disease cases, potentially tapping into a niche market with high unmet medical needs.

For detailed information about MNPR stock, go to TipRanks’ Stock Analysis page.